Management of patients with pre-dementia cognitive impairment
https://doi.org/10.37586/2686-8636-3-2025-332-342
Abstract
Cognitive disorders are one of the most significant problems for elderly and senile people. Particular attention should be paid to the diagnosis of early pre-dementia stages of cognitive impairment: subjective and subtle cognitive decline and mild cognitive impairment. The review presents current concepts of classification of pre-demential forms of cognitive decline, their diagnosis, and therapeutic approaches to managing patients with these disorders. Non-pharmacological methods for managing patients with initial forms of cognitive declines are discussed. The importance of cognitive training, physical activity, and socialization for such patients is highlighted. When considering drug therapy for pre-demetial cognitive impairment, the safety profile of medications is discussed, especially in the elderly population, where it is important. Finding safe and well-tolerated medications for elderly patients remains a priority for specialists. The possibility of using Prospekta in the management of patients with early cognitive decline is being considered.
Keywords
pre-dementia cognitive impairment,
subjective cognitive decline,
subtle cognitive decline,
mild cognitive impairment,
cognitive training,
neuroprotection,
Prospekta
Supporting agencies: The work was carried out with the support of RPC MATERIA MEDICA HOLDING LLC.
About the Author
N. N. Koberskaya
Faculty of General Medicine, Sechenov First Moscow State Medical University of the Ministry of Heath of the Russian Federation (Sechenov University); Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation (Pirogov University), Russian Gerontological Research and Clinical Center
Russian Federation
Russian Federation
Koberskaya Nadezhda Nikolaevna
Moscow
References
1. Petersen R. C. Mild Cognitive Impairment. Continuum (Minneap Minn). 2016 ; 22 (2 Dementia) : 404–418. doi: 10.1212/CON.0000000000000313.
2. Seo E. H., Kim H., Choi K. Y., et al. Pre-Mild Cognitive Impairment: Can Visual Memory Predict Who Rapidly Convert to Mild Cognitive Impairment? Psychiatry Investig. 2018 ; 15 (9) : 869–875. doi: 10.30773/pi.2018.07.29.1.
3. Papp K. V., Buckley R., Mormino E., et al. Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimers Dement. 2020 ; 16 (3) : 552–560. doi: 10.1016/j.jalz.2019.09.074.
4. Yahno N. N. Kognitivnye rasstrojstva v nevrologicheskoj klinike. Nevrologicheskij zhurnal. 2006 ; 11 (1) :4–12 (In Russ.)].
5. Jessen F., Amariglio R. E., van Boxtel M., et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014 ; 10 (6) : 844–852. doi: 10.1016/j.jalz.2014.01.001.
6. Koberskaya N. N., Ostroumova T. M. Near-moderate cognitive decline. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020 ; 12 (2) : 92–97. (In Russ.)]. doi: 10.14412/2074-2711-2020-2-92-97.
7. Edmonds E. C., Delano-Wood L., Galasko D. R., et al. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. J Alzheimers Dis. 2015 ; 47 (1) : 231–242. doi: 10.3233/JAD-150128.
8. Reisberg B., Shulman M. B., Torossian C., et al. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement. 2010 ; 6 (1) : 11–24. doi: 10.1016/j.jalz.2009.10.002.
9. Amariglio R. E., Becker J. A., Carmasin J., et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012 ; 50 (12) : 2880–2886. doi: 10.1016/j.neuropsychologia.2012.08.011.
10. Perrotin A., Mormino E. C., Madison C. M., et al. Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol. 2012 ; 69 (2) : 223–229. doi: 10.1001/archneurol.2011.666.
11. Amieva H., Le Goff M., Millet X., et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol. 2008 ; 64 (5) : 492–498. doi: 10.1002/ana.21509.
12. Caracciolo B., Gatz M., Xu W., et al. Differential distribution of subjective and objective cognitive impairment in the population: a nation-wide twin-study. J Alzheimers Dis. 2012 ; 29 (2) : 393–403. doi: 10.3233/JAD-2011-111904.
13. Koberskaya N. N., Yahno N. N., Gridin V. N., Smirnov D. S. Influence of cardiovascular risk factors on pre-mild cognitive decline at middle and old age. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021 ; 13 (1) : 13–17. (In Russ.)]. doi: 10.14412/2074-2711-2021-1-13-17.
14. Koberskaya N. N., Ostroumova T. M., Perepelov V. A., Smirnov D. S. Influence of genetic and comorbid emotionalaffective factors on pre-mild cognitive decline in middle-aged patients. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics . 2021 ; 13 (4) : 66–74. (In Russ.)]. doi: 10.14412/2074-2711-2021-4-66-74.
15. Koberskaya N. N., Mhitaryan E. A., Lokshina A. B., Grishina D. A. Pre-dementia cognitive impairment. Russian Journal of Geriatric Medicine. 2022 ; (1) : 48–57. (In Russ.)]. doi: 10.37586/2686-8636-1-2022-48-57.
16. Захаров В. В., Громова Д. О. Современные подходы к ведению пациентов с умеренными когнитивными нарушениями. // Журнал неврологии и психиатрии им. С. С. Корсакова. — 2017. — Т. 117, № 3. — С. 107– 112. [Zacharov V. V., Gromova D. O., Current approaches to management of patients with mild cognitive impairment. S. S. Korsakov Journal of Neurology and Psychiatry. 2017 ; 117 (3) : 107–112. (In Russ.)]. doi: 10.17116/jnevro201711731107-112.
17. Imtiaz B., Tolppanen A. M., Kivipelto M., Soininen H. Future directions in Alzheimer's disease from risk factors to prevention. Biochem Pharmacol. 2014 ; 88 (4) : 661–670. doi: 10.1016/j.bcp.2014.01.003.
18. McAlister C., Schmitter-Edgecombe M. Everyday functioning and cognitive correlates in healthy older adults with subjective cognitive concerns. Clin Neuropsychol. 2016 ; 30 (7) : 1087–1103. doi: 10.1080/13854046.2016.1190404.
19. Tkacheva O. N., Runikhina N. K., Mkhitaryan E. A., et al. The effect of physical health and functional status on cognitive functions in women aged 55–64 years old. Advances in gerontology = Uspekhi gerontologii. 2021 ; 34 (3) : 345–351. (In Russ.)]. doi: 10.34922/AE.2021.34.3.002.
20. Davis D. G., Schmitt F. A., Wekstein D. R., Markesbery W. R. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999 ; 58 (4) : 376– 388. doi: 10.1097/00005072-199904000-00008.
21. Stern Y. Cognitive reserve. Neuropsychologia. 2009 ; 47 (10) : 2015–1028. doi: 10.1016/j.neuropsychologia.2009.03.004.
22. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc. 2002 ; 8 (3) : 448–460. doi: 10.1017/s1355617702813248.
23. Koberskaya N. N., Tabeea G. R. The modern concept of cognitive reserve. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019 ; 11 (1) : 96–102. (In Russ.)]. doi: 10.14412/2074-2711-2019-1-96-102.
24. Werner P. Knowledge about symptoms of Alzheimer's disease: correlates and relationship to help-seeking behavior. Int J Geriatr Psychiatry. 2003 ; 18 (11) : 1029–1036. doi: 10.1002/gps.1011.
25. Canevelli M., Adali N., Tainturier C., et al. Cognitive interventions targeting subjective cognitive complaints. Am J Alzheimers Dis Other Demen. 2013 ; 28 (6) : 560–567. doi: 10.1177/1533317513494441.
26. Greenwood P. M., Parasuraman R. Neuronal and cognitive plasticity: a neurocognitive framework for ameliorating cognitive aging. Front Aging Neurosci. 2010 ; 2 : 150. doi: 10.3389/fnagi.2010.00150.
27. Jellinger K. A., Attems J. Neuropathological approaches to cerebral aging and neuroplasticity. Dialogues Clin Neurosci. 2013 ; 15 (1) : 29–43. doi: 10.31887/DCNS.2013.15.1/kjellinger.
28. Tortora C., Di Crosta A., La Malva P., et al. Virtual reality and cognitive rehabilitation for older adults with mild cognitive impairment: A systematic review. Ageing Res Rev. 2024 ; 93 : 102146. doi: 10.1016/j.arr.2023.102146.
29. Low L. F., Harrison F., Lackersteen S. M. Does personality affect risk for dementia? A systematic review and meta-analysis. Am J Geriatr Psychiatry. 2013 ; 21 (8) : 713–728. doi: 10.1016/j.jagp.2012.08.004.
30. Yu X. H., Li X. R., Du Z. R., et al. Effects of nonpharmacological interventions for adults with subjective cognitive decline: a network meta-analysis and component network meta-analysis. BMC Med. 2024 ; 22 (1) : 272. doi: 10.1186/s12916-024-03491-z.
31. Lenze E. J., Voegtle M., Miller J. P, et al. Effects of Mindfulness Training and Exercise on Cognitive Function in Older Adults: A Randomized Clinical Trial. JAMA. 2022 ; 328 (22) : 2218–2229. doi: 10.1001/jama.2022.21680.
32. Smart C. M., Karr J. E., Areshenkoff C. N., et al. NonPharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. Neuropsychol Rev. 2017 ; 27 (3) : 245–257. doi: 10.1007/s11065-017-9342-8.
33. Hart T., Tsaousides T., Zanca J. M., et al. Toward a theory-driven classification of rehabilitation treatments. Arch Phys Med Rehabil. 2014 ; 95 (1 Suppl) : S33–44.e2. doi: 10.1016/j.apmr.2013.05.032.
34. Lautenschlager N. T., Cox K. L., Flicker L., et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008 ; 300 (9) : 1027–1037. doi: 10.1001/jama.300.9.1027. Erratum in: JAMA. 2009 ; 301 (3) : 276.
35. Tsai A. Y., Yang M. J., Lan C. F., Chen C. S. Evaluation of effect of cognitive intervention programs for the community-dwelling elderly with subjective memory complaints. Int J Geriatr Psychiatry. 2008 ; 23 (11) : 1172–1174. doi: 10.1002/gps.2050.
36. Rabin L. A., Wang C., Katz M. J., et al. Predicting Alzheimer's disease: neuropsychological tests, self-reports, and informant reports of cognitive difficulties. J Am Geriatr Soc. 2012 ; 60 (6) : 1128–1134. doi: 10.1111/j.1532-5415.2012.03956.x.
37. Rebok G. W., Ball K., Guey L. T., et al. Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc. 2014 ; 62 (1) : 16–24. doi: 10.1111/jgs.12607.
38. Ngandu T., Lehtisalo J., Solomon A., et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 ; 385 (9984) : 2255–2263. doi: 10.1016/S0140-6736(15)60461-5.
39. Sloane P. D., Zimmerman S., Suchindran C., et al. The public health impact of Alzheimer's disease, 2000–2050: potential implication of treatment advances. Annu Rev Public Health. 2002 ; 23 : 213–231. doi: 10.1146/annurev.publhealth.23.100901.140525.
40. Hu M., Wu X., Shu X., et al. Effects of computerised cognitive training on cognitive impairment: a meta-analysis. J Neurol. 2021 ; 268 (5) : 1680–1688. doi: 10.1007/s00415-019-09522-7.
41. Jedrziewski M. K., Ewbank D. C., Wang H., Trojanowski J. Q. The Impact of Exercise, Cognitive Activities, and Socialization on Cognitive Function: Results From the National Long-Term Care Survey. Am J Alzheimers Dis Other Demen. 2014 ; 29 (4) : 372–378. doi: 10.1177/1533317513518646.
42. Mendiola-Precoma J., Berumen L. C., Padilla K., Garcia-Alcocer G. Therapies for Prevention and Treatment of Alzheimer's Disease. Biomed Res Int. 2016 ; 2016 : 2589276. doi: 10.1155/2016/2589276.
43. Franchini F., Musicco M., Ratto F., et al. The LIBRA Index in Relation to Cognitive Function, Functional Independence, and Psycho-Behavioral Symptoms in a Sample of Non- Institutionalized Seniors at Risk of Dementia. J Alzheimers Dis. 2019 ; 72 (3) : 717–731. doi: 10.3233/JAD-190495.
44. Petersen R. C., Joyner M. J., Jack C. R. Jr. Cardiorespiratory Fitness and Brain Volumes. Mayo Clin Proc. 2020 ; 95 (1) : 6–8. doi: 10.1016/j.mayocp.2019.11.011.
45. Davis J. C., Bryan S., Marra C. A., et al. Challenges with cost-utility analyses of behavioural interventions among older adults at risk for dementia. Br J Sports Med. 2015 ; 49 (20) : 1343–1347. doi: 10.1136/bjsports-2013-092743.
46. Giacosa A., Adam-Blondon A. F., Baer-Sinnott S., et al. Alcohol and wine in relation to cancer and other diseases. Eur J Cancer Prev. 2012 ; 21 (1) : 103–108. doi: 10.1097/CEJ.0b013e32834761d3.
47. Mushtaq R., Shoib S., Shah T., Mushtaq S. Relationship between loneliness, psychiatric disorders and physical health? A review on the psychological aspects of loneliness. J Clin Diagn Res. 2014 ; 8 (9) : WE01–WE4. doi: 10.7860/JCDR/2014/10077.4828.
48. Mielke M. M., James B. D. Women who participated in the paid labor force have lower rates of memory decline: Working to remember. Neurology. 2020 ; 95 (23) : 1027–1028. doi: 10.1212/WNL.0000000000010987.
49. Okonkwo O. C., Schultz S. A., Oh J. M., et al. Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology. 2014 ; 83 (19) : 1753–1760. doi: 10.1212/WNL.0000000000000964. Erratum in: Neurology. 2015 ; 84 (9) : 963. doi: 10.1212/WNL.0000000000001434.
50. Speisman R. B., Kumar A., Rani A., et al. Daily exercise improves memory, stimulates hippocampal neurogenesis and modulates immune and neuroimmune cytokines in aging rats. Brain Behav Immun. 2013 ; 28 : 25–43. doi: 10.1016/j.bbi.2012.09.013.
51. Iso-Markku P., Kujala U. M., Knittle K., et al. Physical activity as a protective factor for dementia and Alzheimer's disease: systematic review, meta-analysis and quality assessment of cohort and case-control studies. Br J Sports Med. 2022 ; 56 (12) : 701–709. doi: 10.1136/bjsports-2021-104981.
52. Ito K., Chapman R., Pearson S. D., et al. Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors. JAMA Netw Open. 2021 ; 4 (10) : e2129392. doi: 10.1001/jamanetworkopen.2021.29392. Erratum in: JAMA Netw Open. 2024 ; 7 (8) : e2433754. doi: 10.1001/jamanetworkopen.2024.33754.
53. Koberskaya N. N. Cardiovascular risk factors for cognitive deficiency and options for correction. Meditsinskiy sovet = Medical Council. 2022 ; (2) : 35–43. (In Russ.)]. doi: 10.21518/2079-701X-2022-16-2-35-43.
54. Alhalaseh L., Makahleh H., Al-Saleem B., et al. Functional Status in Relation to Common Geriatric Syndromes and Sociodemographic Variables — A Step Forward Towards Healthy Aging. Clin Interv Aging. 2024 ; 19 : 901–910. doi: 10.2147/CIA.S462347.
55. Pickering A. N., Hamm M. E., Dawdani A., et al. Older Patient and Caregiver Perspectives on Medication Value and Deprescribing: A Qualitative Study. J Am Geriatr Soc. 2020 ; 68 (4) : 746–753. doi: 10.1111/jgs.16370.
56. Stewart P. T., Rahman M. B., Chiew A. L., et al. Cognitive impairment following sedative overdose. Clin Toxicol (Phila). 2024 ; 62 (3) : 152–163. doi: 10.1080/15563650.2024.2327554.
57. Prospekta. Summary of Product Characteristics (SPCs) [Electronic resource]. Unified Register of Registered medicines of the Eurasian Economic Union. 2023. (In Russ.)]. Режим доступа: https://pharma. eaeunion.org/pharma/registers/26/ru/register/registeredmedicinal-products/66cdae4330dcf85cade65972, свободный.
58. Biologicheskie lekarstvennye preparaty, poluchennye na osnove gradual’noj tekhnologii. Obshchaya farmakopejnaya stat’ya Gosudarstvennoj farmakopei Rossijskoj Federacii XV izdaniya, OFS.1.7.0001 [Electronic resource]. Institute of Pharmacopoeia and Standardization in the Field of Drug Circulation. (In Russ.)]. Режим доступа: https:// pharmacopoeia.regmed.ru/pharmacopoeia/izdanie-15/1/1-9/ biologicheskie-lekarstvennye-preparaty-poluchennye-naosnove-gradualnoy-tekhnologii/, свободный.
59. Bogolepova A. N., Mhitaryan E. A. Features of pharmacotherapy of vascular cognitive impairment in elderly and senile patients. Russian Journal of Geriatric Medicine. 2024 ; (2) : 124–132. (In Russ.)]. doi: 10.37586/2686-8636-2-2024-124-132.
60. Kamchatnov P. R., Kislyak O. A., Skipetrova L. A., et al. Treatment of asthenic syndrome in outpatient practice: meta-analysis of the results concerning clinical trials of an antiasthenic drug. RMJ. 2024 ; (11) : 19–25. (In Russ.)]. doi: 10.32364/2225-2282-2024-11-4.
61. Levin O. S., Koval'chuk V. V., Putilina M. V., et al. Therapy of Moderate Cognitive Impairment of Various Genesis in Patients with Chronic Somatic Diseases: Results of a Multicenter Open Prospective Observational Program (PARUS). Effektivnaya farmakoterapiya = Effective pharmacotherapy. 2022 ; 18 (43) : 78–83. (In Russ.)]. doi: 10.33978/2307-3586-2022-18-43-78-83.
62. Shvartsman G. I., Skoromets A. A., Zhivolupov S. A., et al. Therapy of moderate cognitive impairment and asthenia in patients with cerebrovascular pathology: results of a prospective observational study. S. S. Korsakov Journal of Neurology and Psychiatry. 2022 ; 122 (8) : 88–94. (In Russ.)]. doi: 10.17116/jnevro202212208188.
Review
For citations:
Koberskaya N.N. Management of patients with pre-dementia cognitive impairment. Russian Journal of Geriatric Medicine. 2025;(3):332-342. (In Russ.) https://doi.org/10.37586/2686-8636-3-2025-332-342
Views:
10
Email this article 